Skip to content

Study · Other design · mouse · 2024

4 results

Canagliflozin protects against hyperglycemia-induced cerebrovascular injury by preventing blood-brain barrier (BBB) disruption via AMPK/Sp1/adenosine A2A receptor.

Liu Z, Hua W, Jin S, Wang Y, Pang Y, Wang B, Zhao N, Song Y, Qi J

European journal of pharmacology9 Feb 2024Cited by 11 (Europe PMC)

PMID38341077 (opens in a new tab)DOI10.1016/j.ejphar.2024.176381 (opens in a new tab)PepBankPUB-38341077
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabOther designMechanism

    Under diabetic conditions, AICAR alleviated increased Sp1 expression.

    In plain wordsIn lab tests, AICAR reduced the diabetes-related rise in Sp1 expression.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseSp1 expression
    Study

    mousen: not reported in source

    Brain microvascular endothelial cells under diabetic conditions
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Canagliflozin or AICAR treatment alleviated these changes.
    3 context sentences
    Summary · context
    Increased Sp1 and adenosine A2A receptor expression and decreased p-AMPK and TJ expression were observed under diabetic conditions.
    Summary · context
    Mouse brain MECs were grown in high glucose (30 mM) to mimic diabetic conditions.
    Summary · context
    We also performed validation studies using AMPK activator (AICAR), inhibitor (Compound C), Sp1 small interfering RNA (siRNA), and adenosine A2A receptor siRNA.
  2. 02LabOther designMechanism

    Under diabetic conditions, AICAR alleviated increased adenosine A2A receptor expression.

    In plain wordsIn lab tests, AICAR reduced the diabetes-related rise in adenosine A2A receptor expression.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseAdenosine A2A receptor expression
    Study

    mousen: not reported in source

    Brain microvascular endothelial cells under diabetic conditions
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Canagliflozin or AICAR treatment alleviated these changes.
    3 context sentences
    Summary · context
    Increased Sp1 and adenosine A2A receptor expression and decreased p-AMPK and TJ expression were observed under diabetic conditions.
    Summary · context
    Mouse brain MECs were grown in high glucose (30 mM) to mimic diabetic conditions.
    Summary · context
    We also performed validation studies using AMPK activator (AICAR), inhibitor (Compound C), Sp1 small interfering RNA (siRNA), and adenosine A2A receptor siRNA.
  3. 03LabOther designMechanism

    Under diabetic conditions, AICAR alleviated decreased p-AMPK expression.

    In plain wordsIn lab tests, AICAR restored p-AMPK expression reduced under diabetic conditions.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreasePhosphorylated AMPK expression
    Study

    mousen: not reported in source

    Brain microvascular endothelial cells under diabetic conditions
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Canagliflozin or AICAR treatment alleviated these changes.
    3 context sentences
    Summary · context
    Increased Sp1 and adenosine A2A receptor expression and decreased p-AMPK and TJ expression were observed under diabetic conditions.
    Summary · context
    Mouse brain MECs were grown in high glucose (30 mM) to mimic diabetic conditions.
    Summary · context
    We also performed validation studies using AMPK activator (AICAR), inhibitor (Compound C), Sp1 small interfering RNA (siRNA), and adenosine A2A receptor siRNA.
  4. 04LabOther designMechanism

    Under diabetic conditions, AICAR alleviated decreased tight junction protein expression.

    In plain wordsIn lab tests, AICAR restored tight junction protein expression reduced under diabetic conditions.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseTight junction protein expression
    Study

    mousen: not reported in source

    Brain microvascular endothelial cells under diabetic conditions
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Canagliflozin or AICAR treatment alleviated these changes.
    3 context sentences
    Summary · context
    Increased Sp1 and adenosine A2A receptor expression and decreased p-AMPK and TJ expression were observed under diabetic conditions.
    Summary · context
    Mouse brain MECs were grown in high glucose (30 mM) to mimic diabetic conditions.
    Summary · context
    We also performed validation studies using AMPK activator (AICAR), inhibitor (Compound C), Sp1 small interfering RNA (siRNA), and adenosine A2A receptor siRNA.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.